Knowledge Distillery

Because of concerns about thrombotic events after vaccination with ChAdOx1 nCoV-19 (Oxford–AstraZeneca), several European countries have recommended…

ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of SARS-CoV-2 virus along with gene coding for signal peptide.…

A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this…

Mental disorders might be a risk factor for severe COVID-19. In this article the authors aimed to assess the specific risks of COVID-19-related…

The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19.

CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years…

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India. It has since then become dominant in some indian regions and UK and further…

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for…

The objective of this prospective, multicentre, observational cohort study was to assess neurological manifestations and quality of life (QoL) three…

This review focuses on new evidence supporting the global immunization strategy for MS patients receiving disease-modifying drugs (DMDs), including…

Acute delirium and other neuropsychiatric symptoms have frequently been reported in COVID-19 patients and are variably referred to as acute…

Whilst respiratory failure in COVID-19 arises from severe interstitial lung involvement, SARS-CoV-2 likely spreads also through the nervous system.